Hhlr Advisors, Ltd. Calliditas Therapeutics Ab Transaction History

Hhlr Advisors, Ltd.

4 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2021 Aug 16, 2021	SELL	$26.02 - $31.17 $24.6 Million - $29.4 Million	-944,716 Closed	0 $0
Q1 2021 May 17, 2021	SELL	$27.01 - $32.92 $2.78 Million - $3.39 Million	-102,971 Reduced 9.83%	944,716 $26.1 Million
Q4 2020 Feb 12, 2021	BUY	$23.34 - $36.65 $16.3 Million - $25.6 Million	697,687 Added 199.34%	1,047,687 $35.6 Million
Q2 2020 Aug 14, 2020	BUY	$19.17 - $23.2 $6.71 Million - $8.12 Million	350,000 New	350,000 $8.16 Million

827K

8.5K

26.6K

Ticker CALT
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 26,624,800
Market Cap $1.06B
Description
Calliditas Therapeutics AB (publ), a clinical-stage biopharmaceutical company, focused on identifying, developing, and commercializing pharmaceuticals products for treatments in orphan indications with initial focus on renal and hepatic diseases. It offers Nefecon, an oral formulation of budesonide that is an immunosuppressant for the treatment ...

Get notified when there are updates to the investment portfolio of Hhlr Advisors, Ltd., based on Form 13F filings with the SEC.

Stay updated on Hhlr Advisors, Ltd. with notifications on news.